As healthcare providers brace for potentially seismic shifts in reimbursement under the new administration, pharmaceutical companies face a critical challenge: keeping their treatments accessible and top of mind as providers navigate unprecedented financial uncertainty.
New research from Shapiro+Raj reveals a stark reality: changes to insurance reimbursement and Medicare/Medicaid funding rank among providers’ top concerns – a glaring signal to pharma companies that prescriber decisions could soon be shackled by financial constraints. The question isn’t just how providers will adapt, but whether pharma is prepared to weather this storm alongside them.
Reimbursement Changes Loom Large
Among healthcare providers, insurance changes rank as one of the most pressing concerns related to the new administration, second only to vaccine policies. The research shows that 49% of healthcare professionals believe Medicare/Medicaid funding changes will significantly impact their practice, while 47% express serious concerns about insurance reimbursement changes.
Providers link expected healthcare policy upheavals to their reimbursement concerns. Many fear that dismantling the Affordable Care Act (ACA) without a clear alternative could lead to reduced coverage for underserved populations, ultimately resulting in lower physician reimbursements. Physicians shared their concerns, “They will plan to revoke the ACA but without clear alternative” which could result in “poor coverage for the underserved populations and less reimbursement for physicians making it difficult for practices to thrive.”
Some express apprehension that increased insurance company autonomy under the new administration could lead to wrongful payment denials and increased costs for patients. “Insurance companies will lack regulation and thus deny payments wrongfully, increasing costs to patients.” Many anticipate rising compliance burdens as “insurance companies will create meaningless documentation requirements in order to discourage physicians from ordering or doing anything.”
Yet, some providers see potential positive change, citing “a desire to decrease bureaucracy in medicine and reduce administrative burden” as a priority for the new administration.
The Great Shift Away from Independent Practices
Declining reimbursement, rising inflation, and escalating operational costs are causing what some describe as “a perfect storm” for smaller, independent practices. One physician explained, “The dwindling reimbursement is a big concern because our workers, the nurses, physician assistants, front desk staff see their costs increasing and want raises and meanwhile our reimbursements are decreasing.”
The result? Many independent practices are being forced to contemplate consolidation with larger healthcare systems. One provider lamented, “Unfortunately, we are on the verge of selling our practice to a large health network due to inadequate payment for services.” This trend threatens to reshape the healthcare landscape, potentially limiting patient choice and altering care delivery models.
Impact on Patient Care
The potential changes in reimbursement policies raise serious concerns about patient care, especially for vulnerable populations. Providers worry about a domino effect whereby reduced reimbursements compromise access to care for underserved communities. One provider specifically highlighted the risk to “lower socioeconomic class due to downstream effects of reduced coverage/access/affordability,” while another emphasized the potential impact on “underinsured and indigent patients” who rely on safety net health systems.
The response from providers? Defensive cost-control strategies. A striking 79% report they are controlling costs and taking a cautious approach. However, this defensive stance has implications for healthcare delivery and access.
Implications for Pharma
Pharmaceutical companies must rethink their strategies to stay ahead of the expected reimbursement shakeup. As independent practices increasingly merge into larger healthcare systems, companies need a dual approach: maintaining relationships with individual providers while engaging robustly with institutional entities. This entails understanding formulary committees and treatment protocols while demonstrating clear economic and clinical value at both the provider and institutional levels.
Pharma companies have an opportunity to play a more supportive role in alleviating the growing administrative burdens on providers. This includes developing streamlined prior authorization processes, efficient appeals navigation tools, and dedicated insurance documentation support. By creating digital platforms that simplify authorization procedures, pharmaceutical companies can empower practices to stay focused on patient care rather than bureaucracy.
The industry must go further. Simplified processes shouldn’t stop at treatments, but also diagnostic procedures and other tests that patients may need on their journey to diagnosis or advanced care. The key is clear: pharma companies that make life easier for providers while demonstrating value will emerge as trusted partners amid the chaos.
Stay tuned for the next installment in our four-part series where we unpack healthcare access for vulnerable populations.
Missed Part 1? United Purpose, Divided Perspectives: Healthcare Providers Navigate an Uncertain Future
At Shapiro+Raj, we’re passionate about helping our clients navigate the complex landscape of drug development and commercialization. Our team of social scientists, strategists, and analysts, combine deep therapeutic knowledge with future forward methodologies to deliver actionable insights that drive success.
Contact us at [email protected] to start a conversation about how we can shape the future, together.